Watson Pharmaceuticals Inc. said Thursday it began selling a generic version of Novartis AG's Alzheimer's disease drug Exelon.
Watson said it started shipping generic exelon, or rivastigmine, in doses of 1.5, 3, 4.5, and 6 milligrams. The drug is used to treat dementia in Alzheimer's patients.
Watson said U.S. sales of Exelon were $425 million in the 12 months ended April 30.
Novartis, a Swiss drugmaker, agreed to let Watson launch a generic version of Exelon as part of a patent lawsuit settlement in December 2007.
In morning trading, Watson stock -- WPI -- slid 52 cents to $40.05 and Novartis shares rose 10 cents to $48.42.
Source: Bloomberg Business Week
- 60 Good Reasons to Subscribe to the Alzheimer's Reading Room
- Alzheimer's CareGiving -- Insight and Advice
- Test Your Memory for Alzheimer's (5 Best Self Assessment Tests)
- Communicating in Alzheimer's World
- Worried About Alzheimer's Disease -- You Should Be
- What is Alzheimer's? What are the Eight Types of Dementia?
- Does the Combination of Aricept and Namenda Help Slow the Rate of Decline in Alzheimer's Patients
- Alzheimer's Disease Statistics
- Is it Really Alzheimer's or Something Else?
- Ten Symptoms of Early Stage Alzheimer's
- Ten Tips for Communicating with an Alzheimer’s Patient
The Alzheimer's Action Plan
300 Tips for Making Life Easier
Bob DeMarco is the editor of the Alzheimer's Reading Room and an Alzheimer's caregiver. Bob has written more than 1,610 articles with more than 8,000 links on the Internet. Bob resides in Delray Beach, FL.
Original content Bob DeMarco, the Alzheimer's Reading Room